Navigation Links
Nuvelo Reports Second Quarter 2008 Financial Results
Date:7/23/2008

08 or first quarter of 2009."

2008 Guidance and Key Milestones

Nuvelo is reiterating its prior guidance for 2008 net cash used in operating activities to be in the range of $43.0 to $48.0 million. As a result of the goodwill impairment charge in the second quarter of 2008, the guidance for total operating expenses in 2008 has been revised to be in the range of $52.0 to $57.0 million.

Nuvelo anticipates accomplishing the following near-term milestones:

-- Trial completion and top-line data from the Phase 1b bolus plus infusion trial with NU172 within the next several weeks;

-- Initiation of a Phase 2 trial with NU172 in CABG procedures in the fourth quarter of 2008 or first quarter of 2009;

-- Initiation of a Phase 1 single ascending dose (SAD) trial with NU206 in healthy volunteers within the next several weeks;

-- Trial completion and top-line data from the Phase 1 SAD trial with NU206 in healthy volunteers in the second half of 2008;

-- Initiation of a Phase 1b multiple ascending dose (MAD) trial with NU206 in healthy volunteers in the fourth quarter of 2008 or first quarter of 2009; and

-- Advancement of a new candidate from either the Wnt Therapeutics or the Leukemia Therapeutics Program in 2008.

Conference Call Information

Nuvelo will hold a conference call today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss this announcement. To participate in the conference call, please dial 866-854-8095 for domestic callers and 706-634-8567 for international callers and reference conference passcode, 52257433. A telephone replay of the conference call will be available through Saturday, July 26, 2008. To access the replay, please dial 800-642-1687 for domestic callers and 706-645-9291 for international callers and reference conference passcode, 52257433. In addition, this call is being webcast by Thomson/CCBN and can be accessed at Nuvelo's website at '/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... , Aug. 26, 2014  ViveBio, LLC ... sample collection, stabilization and transportation, announced today that ... Procurement Services, LLC (LPS) of Knoxville, ... products in the United States ... class of ambient temperature dried biological specimen transport ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 Vycom announced ... CA, which specializes in chemical process equipment, has selected ... State University’s Facility for Rare Isotope Beams (FRIB). ... precision cleaning line made with Vycom’s Flametec PVC-C and ... are the essential parts of FRIB’s linear accelerator (known ...
(Date:8/26/2014)... 2014  Guardant Health, a healthcare company focused ... products, has been recognized today by the World ... . As an innovator in non-invasive, tumor profiling, ... a wide variety of industries and regions to ... ® , Guardant Health,s first commercially available product, ...
(Date:8/26/2014)... 26, 2014 After searching for ... research facilities , the University of Kansas Medical ... have chosen iLab Solutions' web-based core facility management ... , "We are very pleased that the ... Center signed on with us,” stated Heather Lorenz, ...
Breaking Biology Technology:ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 2The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 3
... Company also Initiates the Phase 2b ASTUTE Clinical Trial ... Therapeutics, Inc., a privately held biopharmaceutical company, announced that ... the treatment of patients with low-grade hepatic encephalopathy was ... the European Association for the Study of Liver Disease ...
... palliation as an acceptable primary endpoint, ... WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... has reached an agreement with the U.S. Food and ... Phase 3 registration trial of OGX-011, its lead product ...
... compliance and persistence with chronic medications. Prescription refills increase up ... free service offers coaching, reminders and pharmacist support to alleviate ... - prescribed medication. , ... ...
Cached Biology Technology:Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 2Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6New Pleio Medication Adherence Service Increases Prescription Refills Up To 53% 2
(Date:8/26/2014)... in St. Louis have developed algorithms to identify weak ... or breaking. The technology, which needs to be refined ... help pinpoint minor strains and tiny injuries in the ... research is available online Aug. 27 in the ... research at the nexus of the physical and life ...
(Date:8/26/2014)... a pen a New Zealand endemic tree has for the ... group of ,weedy, Australian shrubs and small trees. A New ... surprises and discover astonishing cryptic diversity behind what was long ... the open access journal PhytoKeys . , ... was one of the many discoveries made in the north-western ...
(Date:8/26/2014)... -- Unregulated trash burning around the globe is pumping ... official records. A new study led by the National ... percent of the world,s garbage is burned in such ... human health and climate change. , The new study ... of pollutants such as particulates, carbon monoxide, and mercury ...
Breaking Biology News(10 mins):New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 2And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 3Trash burning worldwide significantly worsens air pollution 2Trash burning worldwide significantly worsens air pollution 3
... Fifty-nine leading life scientists from Europe and around the ... Organization (EMBO) for their proven excellence in research. Fifty-one ... Europe and neighbouring countries, while eight equally respected scientists ... as Associate Members, bringing the current membership total to ...
... herbicide that is effective at killing broadleaf weeds in ... Illinois and other Midwestern states, may finally have a ... developed a new grape called Improved Chancellor which is ... 1946, 2,4-Dichlorophenoxyacetic or 2, 4-D was introduced. It was ...
... is available in Spanish . An ... the Institute for Research in Biomedicine (IRB Barcelona) and ... (ICIQ, Tarragona), have discovered a substance with the capacity ... certain mutations that promote the appearance of cancer. Giralt, ...
Cached Biology News:EMBO honors 59 leading life scientists 2Herbicide-resistant grape could revitalize Midwest wine industry 2Herbicide-resistant grape could revitalize Midwest wine industry 3Design of a compound that stabilizes the main natural suppressor of tumors 2
... Clear yellow solution. In ... thimerosal, and other proprietary ... Diluent formulated to stabilize ... antibody conjugates at high ...
... software is used to predict ... DNA sequence up to 3,200 ... placement of primers and GC ... denaturing gradient gel electrophoresis (DGGE), ...
... The Mini-Sub cell GT cell and PowerPac ... gel electrophoresis of nucleic acids in agarose gels. ... tank, lid with cables and electrodes, a 7 ... ruler, two casting gates, and two 1.5 mm ...
... PowerPac basic power supply are used for submerged ... gels. The mini format cell includes a buffer ... bubble. The PowerPac basic power supply, 100-120 and ... mA, and 75 W. Power cord and instructions ...
Biology Products: